In particular, oral administration of Bergacyn® reduced oxidative stress (GPx, SOD and MDA) and inflammatory biomarkers (TNF-α), contributing to a significant improvement of vascular inflammation and NO-mediated vasodilation in patients with NAFLD and type 2 diabetes [90]. The gene discussed is TNF; the disease is type 2 diabetes mellitus.